Stocklytics Platform
Asset logo for symbol BMRN
BioMarin Pharmaceutical
BMRN82
$61.53arrow_drop_up0.37%$0.22
High Quality
Asset logo for symbol BMRN
BMRN82

$61.53

arrow_drop_up0.37%
Key Stats
Open$61.67
Prev. Close$61.25
EPS1.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range61.02
62.33
52 Week Range60.62
99.56
Ratios
EPS1.66
Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BMRN-
US Healthcare Sector-
US Market-
warning

BMRN / Market

BMRN lose to the US Market which returned 1.31% over the last twenty four hours.
warning

BMRN / Healthcare Sector

BMRN lose to the US Healthcare sector which returned 2.66% over the last twenty four hours.

BioMarin Pharmaceutical (BMRN) Statistics

BioMarin Pharmaceutical Inc., BMRN, is a global biotechnology company specializing in developing and commercializing innovative therapies for rare genetic diseases. With a focus on genetic medicine, BioMarin aims to provide transformative treatments for patients with unmet medical needs. The company's mission is to push the boundaries of science and deliver therapies that can significantly improve the lives of individuals affected by rare diseases.
When it comes to stock statistics, BioMarin Pharmaceutical Inc. has established itself as a leader in the biotechnology sector. As of the latest available data, BMRN has a market capitalization of over $15 billion, making it one of the larger companies in the industry. The stock has shown impressive performance over the years, consistently outperforming its sector. Investors have benefited from the company's strong fundamentals and its ability to generate substantial revenue per share. The enterprise to EBITDA ratio, a key valuation metric, is also favorable, indicating the company's ability to generate earnings from its operations.
add BioMarin Pharmaceutical  to watchlist

Keep an eye on BioMarin Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has BioMarin Pharmaceutical (BMRN) stock's performance compared to its sector and the market over the past year?

Over the past year, BioMarin Pharmaceutical (BMRN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.60%, BioMarin Pharmaceutical has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 47.53%, it has fallen short of the market average. This comparison highlights BioMarin Pharmaceutical 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of BioMarin Pharmaceutical (BMRN) stock?

The PE (Price to Earnings) ratio of BioMarin Pharmaceutical (BMRN) is currently 37.07. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of BioMarin Pharmaceutical (BMRN) stock?

The Earnings Per Share (EPS) for BioMarin Pharmaceutical (BMRN), calculated on a diluted basis, is $1.66. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of BioMarin Pharmaceutical (BMRN) stock?

The operating margin for BioMarin Pharmaceutical (BMRN) is 15.27%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of BioMarin Pharmaceutical (BMRN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of BioMarin Pharmaceutical (BMRN) is $496.72M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does BioMarin Pharmaceutical (BMRN) have?

BioMarin Pharmaceutical (BMRN) has a total debt of $602.69M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$72.76M.

Take Your Investments to a Whole New Level